^
Association details:
| Biomarker: | EGFR exon 20 mutation + EGFR V774M + EGFR S768I |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Ameile (aumolertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Exceptional Response to Aumolertinib in an Advanced NSCLC Patient With Rare EGFR Exon20 V774M and S768I Mutations
Published date:
08/08/2023
Excerpt:
We reported a case of aumolertinib for treating an advanced NSCLC patient with rare complex mutations of EGFR exon20 V774M/S768I….Two months post-radiotherapy, disease progression was observed in both the lung and brain. Based on the disease progression, aumolertinib was administered in combination with the anti-angiogenic drug anlotinib, resulting in stable disease(SD). The PFS1 of aumolertinib monotherapy was approximately 11 months.... Importantly, this case is the first report of aumolertinib being applied to EGFR V774M/S768I mutations (monotherapy PFS: 11 months), providing meaningful insight into potential regimens for patients harboring these complex mutations.
